University of California

Chiron Corporation

Cetus Corporation

Cold Spring Harbor Laboratory

Cetus Oncology Corporation

Robin Clark

Francis P McCormick

Gail L Wong

Ian J Mohr

Michael R Botchan

Danute E Nitecki

George A Martin

Bonnee Rubinfeld

Norman Arnheim

Shaw Sun

Edward C O'Rourke

Kirston E Koths

Robert F Halenbeck

Rong Li

Liu Yang

James R Feramisco

Medicaments, and methods of identifying the same, are described that are useful for treating papillomavirus diseases that have the characteristics of preventing, interfering with, or reversing the binding of the appropriate papillomavirus proteins E1 or E2 to a nucleotide sequence homologous to a nucleotide sequence present in the papillomavirus genome, or of the formation of a complex consisting of papillomavirus proteins E1 and E2, or the binding of the complex to the nucleotide sequence.

Medicaments for the treatment of papillomavirus diseases

Native Type II GAP (GTPase activating protein), its uses in cancer diagnosis, and methods for obtaining and purifying native and recombinant Types I and II GAPs are described.

Native type II GAP, methods for purifying various GAPs and uses of GAPs

Guanosine triphosphatase activating protein (GAP) DNA sequences are described that are useful as cancer diagnostics, particularly to detect cancer cells that express the ras oncogene protein p21 by measuring the level of GAP gene expression or amplification.

Gap gene sequences

Compositions and methods for identifying inhibitors of papilloma virus replication are described consisting of soluble cellular extracts supplemented with purified viral E1 and E2 proteins.

Methods and compositions for identifying inhibitors of papilloma virus

Compositions for identification of papillomavirus replication inhibitors

Antibodies exhibit specificity toward single amino acid differences between proteins. These antibodies may be produced by synthesizing a peptide of the appropriate amino acid sequence contained in the protein, immunizing a host with the peptide, and extracting sera from the host to obtain the antibodies. The antibodies and the desired protein are then immunoprecipitated under conditions of partial denaturation to expose the epitope of the protein. The antibodies may be used for diagnostic or therapeutic purposes.

Peptide antibodies and their use in detecting oncogene products

Growing community of inventors

Oakland, CA, United States of America

Robin Clark